Stay updated with breaking news from Pascal Deschatelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its target price boosted by Citigroup from $88.00 to $106.00 in a report published on Monday morning, The Fly reports. Several other research firms have also commented on APLS. HC Wainwright increased their price target on shares of Apellis Pharmaceuticals from $87.00 to $100.00 in a research report […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its price target raised by Bank of America from $112.00 to $114.00 in a report published on Friday, The Fly reports. APLS has been the topic of several other research reports. HC Wainwright boosted their price objective on Apellis Pharmaceuticals from $87.00 to $100.00 in a report on […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) has earned an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) issued its quarterly earnings data on Thursday. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.14), Briefing.com reports. The business had revenue of $44.80 million during the quarter, compared to the consensus estimate of $26.10 million. Apellis Pharmaceuticals had a […]